Cargando…
Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications
Diffuse large B-cell lymphoma (DLBCL) represents a group of tumors characterized by substantial heterogeneity in terms of their pathological and biological features, a causal factor of their varied clinical outcome. This variation has persisted despite the implementation of rituximab in treatment re...
Autores principales: | Papageorgiou, Sotirios G., Thomopoulos, Thomas P., Katagas, Ioannis, Bouchla, Anthi, Pappa, Vassiliki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150462/ https://www.ncbi.nlm.nih.gov/pubmed/34104369 http://dx.doi.org/10.1177/20406207211013987 |
Ejemplares similares
-
Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab
por: Papageorgiou, Sotirios G., et al.
Publicado: (2022) -
Multiple osteolytic lesions due to Double-Expressor Primary non-Hodgkin Lymphoma of the Bone
por: Papageorgiou, Sotirios, et al.
Publicado: (2020) -
The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era
por: Kobayashi, T, et al.
Publicado: (2016) -
Discontinuation of the renin–angiotensin system inhibitors improves erythropoiesis in patients with lower-risk myelodysplastic syndromes
por: Pavlidis, George, et al.
Publicado: (2021) -
PB1740: THE COMBINATION OF PONATINIB PLUS CHEMOTHERAPY UPFRONT ACHIEVES DURABLE COMPLETE MOLECULAR REMISSIONS IN ADULTS PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA.
por: Sotirios, Papageorgiou, et al.
Publicado: (2023)